Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

• Alexander Egeberg,
• Joseph F. Merola,
• Knut Schäkel,
• Luis Puig,
• Patrick D. Mahar,
• Patrick D. Mahar,
• Isabella Yali Wang,
• Imre Pavo,
• Christopher Schuster,
• Christopher Schuster,
• Christopher E. M. Griffiths

Affiliations

Alexander Egeberg

Bispebjerg and Frederiksberg Hospital, Copenhagen University, Copenhagen, Denmark

Joseph F. Merola

Division of Rheumatology, Department of Dermatology and Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States

Knut Schäkel

Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany

Luis Puig

Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Patrick D. Mahar

Eli Lilly and Company, Indianapolis, IN, United States

Patrick D. Mahar

Department of Dermatology, Royal Children's Hospital, Faculty of Medicine, Nursing and Health Sciences, Skin Health Institute, The University of Melbourne, Melbourne, VIC, Australia

Isabella Yali Wang

Eli Lilly and Company, Indianapolis, IN, United States

Imre Pavo

Eli Lilly and Company, Indianapolis, IN, United States

Christopher Schuster

Eli Lilly and Company, Indianapolis, IN, United States

Christopher Schuster

Department of Dermatology, Medical University of Vienna, Vienna, Austria

Christopher E. M. Griffiths

Dermatology Centre, Salford Royal Hospital, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom